Full Press Release Details
Announces First Patient Treated with CGuardTM EPS in India
with severe stenosis, calcification and thrombosis successfully treated with CGuardTM EPS
Aviv, Israel- March 5, 2018 - InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus
management technologies and neurovascular devices, today announced successful treatment of the first patient in India with CGuard
EPS. The case was performed at Shri B. D Mehta Mahavir Hospital in the city of Surat, Gujarat state, by Dr. Hiral Shah, a leading
interventional neuro-radiologist.
first case in India follows the recently announced exclusive distribution agreement for CGuard EPS with Hester Diagnostics
Pvt. Ltd., as well as recent regulatory and marketing clearance granted by India's Central Drugs Standard Control Organisation
within the Ministry of Health & Family Welfare.
Gandhi, Managing Director of Hester Diagnostics,
commented, "The patient in this case had severe stenosis with the carotid artery occluded by more than 80 percent, including
blockage of blood flow through the left common carotid artery, and the patient was experiencing transient ischemic attacks. Following
the procedure, Dr. Shah reported complete procedural success using CGuard EPS. We are very happy with the product performance,
as anticipated, and look forward to rolling out CGuard EPS broadly across India."
Gago, EVP and Chief Commercial Officer of InspireMD, commented, "We are extremely pleased by how quickly the first procedure
was performed in India following regulatory and marketing clearance and announcing our distribution partnership with Hester Diagnostics.
The speed in which this was done not only underscores our distributor capabilities but having CGuardTM EPS used in
India also represents a milestone in our expansion efforts across Asia."
seeks to utilize its proprietary MicroNet technology to make its products the industry standard for embolic protection
and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization,
no reflow and major adverse cardiac events.
intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard ), neurovascular, and peripheral
artery procedures. InspireMD's common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants
are quoted on the NYSE American under the ticker symbol NSPR.WS.
press release contains "forward-looking statements." Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential"
or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are
subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot
be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking
statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance
of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability
to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much
larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities
and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third
party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering
our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and
foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need
to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive
or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign
currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws
and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors
that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities
and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.
The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information,
future events or otherwise.